Guohai Securities released a research report on April 25 stating that it gave Xinhecheng (002001.SZ) a purchase rating. The main reasons for the rating include: 1) the company's 2023 performance declined year-on-year due to narrowing profits from nutritional products; 2) the price of vitamins and methionine rebounded steadily, and the first quarter's performance improved significantly; 3) the continuous progress of various projects drove the company's continued growth. (Mainichi Keizai Shimbun)
国海证券4月25日发布研报称，给予新和成（002001.SZ）买入评级。评级理由主要包括：1）营养品盈利收窄致业绩承压，公司2023年业绩同比下降；2）维生素及蛋氨酸价格企稳回升，一季度业绩同环比大幅改善；3）多项目不断推进，驱动公司持续成长。（每日经济新闻）
Guohai Securities released a research report on April 25 stating that it gave Xinhecheng (002001.SZ) a purchase rating. The main reasons for the rating include: 1) the company's 2023 performance declined year-on-year due to narrowing profits from nutritio
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.